Nasopharyngeal Carcinoma

被引：169

作者：

Kamran, Sophia C. ^{[1
]}

Riaz, Nadeem ^{[2
]}

Lee, Nancy ^{[2
]}

机构：

[1] Brigham & Womens Hosp, Harvard Radiat Oncol Program, Boston, MA 02115 USA

[2] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10065 USA

来源：

SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA | 2015年 / 24卷 / 03期

关键词：

Head and neck cancer; Epstein-Barr virus; Nasopharyngeal carcinoma; EBV molecular biology; EPSTEIN-BARR-VIRUS; INTENSITY-MODULATED RADIOTHERAPY; PROGRESSION-FREE SURVIVAL; PHASE-III; CONCURRENT CHEMORADIOTHERAPY; PROGNOSTIC-FACTORS; LATENT MEMBRANE-PROTEIN-1; RADIATION-THERAPY; RANDOMIZED-TRIAL; CHINESE PATIENTS;

D O I：

10.1016/j.soc.2015.03.008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Nasopharyngeal carcinoma is uncommon in the United States, with only 0.2 to 0.5 cases per 100,00 people; this is in contrast to southern China and Hong Kong, where the incidence is 25 to 50 per 100,000 people. There is a potential link between Epstein-Barr virus and the development of nasopharyngeal carcinoma. Radiotherapy alone as a single modality leads to similar 10-year survival rates in United States, Denmark, and Hong Kong (34%, 37%, and 43%, respectively). Multiple studies have shown an advantage to concurrent chemoradiation in the treatment of advanced disease. Radiation therapy remains the mainstay of salvage therapy, and modern techniques have allowed clinicians to achieve adequate local control without excessive toxicity.

引用

页码：547 / +

页数：16

共 77 条

[1] Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized intergroup study 0099 [J].

Al-Sarraf, M ;

LeBlanc, M ;

Giri, PGS ;

Fu, KK ;

Cooper, J ;

Vuong, T ;

Forastiere, AA ;

Adams, G ;

Sakr, WA ;

Schuller, DE ;

Ensley, JF .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) :1310-1317

[2]

[Anonymous], 1992, UNION INT CANC

[3] Life threatening laryngeal toxicity following treatment with combined chemoradiotherapy for nasopharyngeal cancer: A case report with review of the literature [J].

Baron-Hay, S ;

Clifford, A ;

Jackson, M ;

Clarke, S .

ANNALS OF ONCOLOGY, 1999, 10 (09) :1109-1112

[4]

BEAHRS OH, 1992, MANUAL STAGING CANC, P33

[5] CHEMOTHERAPY OF METASTATIC AND OR RECURRENT UNDIFFERENTIATED NASOPHARYNGEAL CARCINOMA WITH CISPLATIN, BLEOMYCIN, AND FLUOROURACIL [J].

BOUSSEN, H ;

CVITKOVIC, E ;

WENDLING, JL ;

AZLI, N ;

BACHOUCHI, M ;

MAHJOUBI, R ;

KALIFA, C ;

WIBAULT, P ;

SCHWAAB, G ;

ARMAND, JP .

JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (09) :1675-1681

[6]

BUELL P, 1974, CANCER RES, V34, P1189

[7] Treatment approaches to nasopharyngeal carcinoma: a review [J].

Caponigro, Francesco ;

Longo, Francesco ;

Ionna, Franco ;

Perri, Francesco .

ANTI-CANCER DRUGS, 2010, 21 (05) :471-477

[8] Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma [J].

Chan, ATC ;

Leung, SF ;

Ngan, RKC ;

Teo, PML ;

Lau, WH ;

Kwan, WH ;

Hui, EP ;

Yiu, HY ;

Yeo, W ;

Cheung, FY ;

Yu, KH ;

Chiu, KW ;

Chan, DT ;

Mok, TSK ;

Yau, S ;

Yuen, KT ;

Mo, FKF ;

Lai, MMP ;

Ma, BBY ;

Kam, MKM ;

Leung, TWT ;

Johnson, PJ ;

Choi, PHK ;

Zee, BCY .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (07) :536-539

[9] Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: Progression-free survival analysis of a phase III randomized trial [J].

Chan, ATC ;

Teo, PML ;

Ngan, RK ;

Leung, TW ;

Lau, WH ;

Zee, B ;

Leung, SF ;

Cheung, FY ;

Yeo, W ;

Yiu, HH ;

Yu, KH ;

Chiu, KW ;

Chan, DT ;

Mok, T ;

Yuen, KT ;

Mo, F ;

Lai, M ;

Kwan, WH ;

Choi, P ;

Johnson, PJ .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (08) :2038-2044

[10] Salvage surgery for locally recurrent nasopharyngeal carcinoma - A 10-year experience [J].

Chang, KP ;

Hao, SP ;

Tsang, NM ;

Ueng, SH .

OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2004, 131 (04) :497-502

← 1 2 3 4 5 6 7 8 →